Seaport Therapeutics, Inc.
SPTX evidence brief
What we can confirm
- Market Cap:
- $1.29B
What it means
What to watch
Prepared research question
What matters most for SPTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SPTX
Seaport Therapeutics is a clinical-stage biotech company developing novel neuropsychiatric medicines using its proprietary Glyph platform, with a lead program in Phase 2 for major depressive disorder and a management team with a track record of prior drug approvals.
Key risk: No revenue until approval
Market Cap
$1.29B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Seaport Therapeutics is a clinical-stage biotech company developing novel neuropsychiatric medicines using its proprietary Glyph platform, with a lead program in Phase 2 for major depressive disorder and a management team with a track record of prior drug approvals.
- Seaport is a clinical-stage therapeutics company focused on inventing and developing new medicines for neuropsychiatric and other CNS disorders using its proprietary Glyph platform [sec · filed 2026-04-27].
- As of June 30, 2026, the company reported cash & equivalents of $64.2M, net income of -$62.6M, and shareholders' equity of $422.6M [sec].
- The company's accumulated deficit was $202.1 million as of August 3, 2026 [sec_mda · as of 2026-08-03].
- Seaport has raised $325 million in net proceeds from leading life science investors including ARCH Venture Partners, General Atlantic, Sofinnova Investments, Third Rock Ventures, and PureTech [sec · filed 2026-04-10].
- The company's co-founders, Daphne Zohar and Dr. Steven Paul, were central to the success of Karuna Therapeutics, which developed Cobenfy, approved by the FDA in September 2024 for schizophrenia [sec · filed 2026-04-27].
What works
- The company's leadership team has a proven track record in neuropsychiatry, having been involved in the development and commercialization of multiple approved drugs including Cobenfy, Latuda, Zyprexa, Cymbalta, and Zurzuvae [sec · filed 2026-04-27].
- Seaport's proprietary Glyph platform is designed to create novel medicines with strong intellectual property by addressing issues that have held back clinically validated mechanisms [sec · filed 2026-04-27].
- The company has secured $325 million from prominent life science investors, indicating significant institutional backing [sec · filed 2026-04-10].
What to weigh
- Seaport has a limited operating history as a standalone company, which may make it difficult to evaluate its current business and predict future success [sec · filed 2026-04-10].
- The company has incurred significant financial losses since inception and expects to continue doing so, with a net loss of $62.6M for the period ending June 30, 2026 [sec] and an accumulated deficit of $202.1M as of August 3, 2026 [sec_mda · as of 2026-08-03].
- Seaport does not expect to generate any revenue from product sales unless and until it successfully completes development and obtains regulatory approval, which may not occur for at least several years, if ever [sec_mda · as of 2026-08-03].
From the filings
Quoted directly from source documents.
Seaport's accumulated deficit as of August 3, 2026
“an accumulated deficit of $202.1 million.”
SEC MD&A · August 3, 2026
Cash runway into 2029 based on June 30, 2026 financials
“as of June 30, 2026, will be sufficient to fund our operations into 2029.”
SEC MD&A · August 3, 2026
Co-founders' role in Karuna Therapeutics and Cobenfy approval
“Our co-founders, Daphne Zohar, and Dr. Steven Paul, were central to the success of Karuna Therapeutics, which invented and advanced the first-in-class medicine Cobenfy, and was acquired by Bristol Myers Squibb in March 2024 for $14 billion.”
SEC filings · April 27, 2026
Seaport's three-pillar approach
“1) identify clinically validated mechanisms held back by issues that can be addressed by our proprietary Glyph platform, 2) create novel medicines with strong intellectual property using Glyph, and 3) apply our team's expertise to optimize the design and execution of clinical trials and drive successful business outcomes.”
SEC filings · April 27, 2026
Catalyst timeline
- 2025-06-19 · Phase2_Start: A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Adults With Major Depressive Disorder (MDD), With or Without Anxious Distress — Initiation of the pivotal Phase 2 efficacy trial for Seaport's lead candidate.
- 2025-09-02 · Phase2_Start: A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults With Major Depressive Disorder, With or Without Anxious Distress — Open-label extension study to gather additional safety and tolerability data.
Risks & what to watch (3)›
Key risks
- No revenue until approval — Seaport does not expect product revenue for at least several years, if ever, and may exhaust capital sooner than expected [sec_mda · as of 2026-08-03].
- Limited operating history — As a standalone company, Seaport's limited history makes evaluation of future success difficult [sec · filed 2026-04-10].
- Significant accumulated losses — Accumulated deficit of $202.1M as of August 3, 2026, with continued net losses expected [sec_mda · as of 2026-08-03].
What to watch
- Phase 2 clinical trial results for SPT-300 in major depressive disorder, which started in June 2025 [catalyst].
- Open-label extension study of SPT-300 in MDD, initiated in September 2025 [catalyst].
- Cash runway updates: management estimates funding into 2029 based on June 30, 2026 cash position, but actual timelines may vary [sec_mda · as of 2026-08-03].
Sources: Catalysts · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Seaport Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Seaport Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Frequently asked questions
What is the AI investment thesis for Seaport Therapeutics, Inc.?
Seaport Therapeutics is a clinical-stage biotech company developing novel neuropsychiatric medicines using its proprietary Glyph platform, with a lead program in Phase 2 for major depressive disorder and a management team with a track record of prior drug approvals.
Who is the CEO of Seaport Therapeutics, Inc.?
Ms. Daphne Zohar is the chief executive officer of Seaport Therapeutics, Inc. (SPTX).
Where is Seaport Therapeutics, Inc. headquartered?
Seaport Therapeutics, Inc. (SPTX) is headquartered in Boston, MA, United States.
What therapeutic areas does Seaport Therapeutics, Inc. focus on?
Seaport Therapeutics, Inc. develops therapies across Oncology, Neurology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.